m6A调节因子在肺腺癌和肺鳞癌中的生物学差异

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (2322 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the biological difference of m6A regulators in lung adenocarcinoma(LUAD) and lung squamous carcinoma(LUSC). Methods The expression profiles of LUAD and LUSC were obtained from the Cancer Genome Atlas (TCGA) database, and R was used to analyze the expression differences of 26 potential target genes of m6A regulators between LUAD and LUSC tumor tissues and normal tissues. The Cancer Proteome Atlas (TCPA) and Reverse phase protein array (RPPA) data were used to calculate the pathway activity scores (PAS) of the 26 m6Aregulators in 10 tumor-related pathways. Univariate COX analysis and Kaplan-Meier survival analysis were used to analyze the impact and difference of potential target genes of m6A regulators on prognosis of LUAD and LUSC patients. Results Among the 26 m6A regulators, the differences in the expression levels of ZCCHC4, ALKBH1 and YTHDF2 were statistically significant only in tumour and normal tissues in LUAD, and the differences in the expression levels of IGF2BP2 and YTHDC2 were statistically significant only in tumour and normal tissues in LUSC. In LUAD and LUSC, there were significant differences in the activity of the pathways involved in the regulation of m6A regulators. METTL3, METTL5, METTL14, ZC3H13, RBMX and FTO only played activating or inhibiting functions in tumour-related pathways such as Apoptosis, Cell cycle, EMT and RAS/MAPK in LUAD, while EIF3A, YTHDC2 and RBM15B only played inhibiting or activating roles in PI3K/AKT and TSC/mTOR signalling pathways in LUSC. The expression of IGF2BP3 and IGF2BP3 regulators was negatively correlated with prognostic survival in LUAD and positively correlated with prognostic survival in LUSC. Conclusions The same m6A regulators may play different regulatory roles in the biological processes of LUAD and LUSC.

Key words： lung adenocarcinoma lung squamous carcinoma m6A differential expression pathway activity prognosis

Received: 20 December 2022

ZTFLH:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIN Hua
	LIU Zhi
	ZHANG Jieli

Cite this article:

XIN Hua,LIU Zhi,ZHANG Jieli. Biological difference of m6A regulators in lung adenocarcinoma and lung squamous carcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(6): 494-500.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I6/494

[1]	Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Zhan C,Yan L,Wang L, et al. Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma[J].J Thorac Dis,2015,7(8):1398-1405.
[3]	An Y, Duan H. The role of m6A RNA methylation in cancer metabolism[J]. Mol Cancer, 2022, 21(1):14.
[4]	Li J, Han Y, Zhang H M, et al.The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA[J].Biochem Biophys Res Commun, 2019, 512(3): 479-485.
[5]	Jin D, Guo J W, Wu Y, et al. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC[J]. Mol Cancer, 2020, 19(1): 40.
[6]	Du Y Z, Hou G F, Zhang H L, et al.SUMOylation of the m6A RNA methyltransferase METTL3 modulates its function[J].Nucleic Acids Res, 2018, 46(10): 5195-5208.
[7]	Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J]. Nature, 2018, 561(7724):556-560.
[8]	Zhao Z, Wan J, Guo M, et al. Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer[J]. J Clin Lab Anal, 2022, 36(1):e24118.
[9]	Qu J, Wang L, Jiang M, et al. Survival-associated N6-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification[J]. BMC Cancer, 2021, 21(1):1265.
[10]	Liu X, Ma C, Liu H, et al. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2022, 148(10):2803-2814.
[11]	Akbani R, Ng P K, Werner H M,et al. A pan-cancer proteomic perspective on the cancer genome atlas[J]. Nat Commun, 2014, 5:3887.
[12]	Ye Y, Xiang Y, Ozguc F M, et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy[J]. Cell Syst, 2018, 6(3):314-328.
[13]	石翔,王朝栋,李珊,等.PET/CT诊断肺腺癌与肺鳞癌的价值观察[J].中国CT和MRI杂志,2022,20(9):47-49.
[14]	段秀杰,李福元,付玉存.周围型非小细胞肺癌CT征象与临床病理分型的关系[J].现代肿瘤医学,2020,28(15):2622-2626.
[15]	Zengin T, Önal-Süzek T. Comprehensive profiling of genomic and transcriptomic differences between risk groups of lung adenocarcinoma and lung squamous cell carcinoma[J]. J Pers Med, 2021, 11(2):154.
[16]	Li N, Wang J, Zhan X. Identification of immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma[J]. Front Immunol, 2021, 12:752643.
[17]	Meng F, Zhang L, Ren Y, et al. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates[J]. J Cell Physiol, 2019, 234(7):10918-10925.
[18]	Zhao Z, Cai Q, Zhang P, et al. N6-Methyladenosine RNA methylation regulator-related alternative splicing (as) gene signature predicts non-small cell lung cancer prognosis[J]. Front Mol Biosci, 2021, 8:657087.
[19]	Yang B, Wang J Q, Tan Y, et al. RNA methylation and cancer treatment[J]. Pharmacol Res, 2021, 174:105937.
[20]	陈俊文,王侠,王科峰. RNA m6A修饰与肿瘤[J].现代肿瘤医学,2020,28(18):3248-3254.
[21]	Sun Z, Su Z, Zhou Z, et al. RNA demethylase ALKBH5 inhibits TGF-β-induced EMT by regulating TGF-β/SMAD signaling in non-small cell lung cancer[J]. FASEB J, 2022, 36(5):e22283.
[22]	Xu X, Zhang P, Huang Y, et al. METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer[J]. Cancer Sci, 2022,12:1458.
[23]	彭伟,史建新,刘博,等. 新型m6A阅读器IGF2BP1在非小细胞肺癌组织中的表达及临床意义[J]. 解剖科学进展,2020,26(1):47-50.
[24]	Zhu H, Chen K, Chen Y, et al. RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis[J]. Signal Transduct Target Ther, 2022, 7(1):240.
[25]	Li H, Zhang Y, Guo Y,et al. ALKBH1 promotes lung cancer by regulating m6A RNA demethylation[J]. Biochem Pharmacol. 2021, 189:114284.
[26]	Tsuchiya K, Yoshimura K, Inoue Y, et al. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1):1962656.
[27]	Han L, Lei G, Chen Z, et al. IGF2BP2 regulates MALAT1 by serving as an N6-Methyladenosine reader to promote NSCLC proliferation[J]. Front Mol Biosci, 2022, 8:780089.
[28]	Wang Y, Li M, Zhang L, et al. m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer[J]. Mol Ther Oncolytics, 2021, 21:367-376.
[29]	Qiu X, Yang S, Wang S, et al. M6A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma[J]. Cancer Res. 2021, 81(18):4778-4793.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(6): 527-529.